治疗变异性及其与患有韦尼克脑病的患者结果的关系:一个多中心的回顾性研究
Ignacio Novo-Veleiro1, Ana-M Mateos-Díaz2, Beatriz Rosón-Hernández3
1Department of Internal Medicine, Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain.
Drug and alcohol dependence
|September 25, 2023
概括
维尼克·韦尔尼克 (Wernicke) 是一个
科学领域:
- 神经学 神经学
- 营养神经科学 营养神经科学
- 内部医学 内部医学
背景情况:
- 韦尼克脑病变 (WE) 治疗指南存在,但缺乏强有力的证据,导致临床实践不一致.
- 对于WE治疗而言,胺剂量管理的变化需要进一步研究最佳剂量和途径.
研究的目的:
- 分析大量患有韦尼克脑病的患者队列中的胺剂量,施用因素和治疗结果关联.
- 确定影响胺治疗变异性的因素及其对患者康复和死亡率的影响.
主要方法:
- 从西班牙全国性注册 (2000-2012) 中对443名被诊断为WE的患者进行了回顾性分析.
- 数据包括人口,临床,诊断 (凯恩标准) 和治疗变量 (胺剂量,频率,途径).
- 评估的结果变量包括完全康复和死亡率.
主要成果:
- 观察到胺治疗方案的显著变化,高剂量静脉注射的发病率较低.
- 延迟诊断,特定的临床表现和叶酸缺乏与不完全康复有关.
- 营养不良,意识变化,叶酸缺乏和提胺治疗延迟被确定为死亡风险因素.
结论:
- 对于维尼克脑病症的管理,胺剂量和给药途径的极端变化需要注意.
- 实施确保遵守指导方针和解决风险人群营养缺陷的措施至关重要.
更多相关视频
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
579
12:49Transcranial Direct Current Stimulation tDCS of Wernicke's and Broca's Areas in Studies of Language Learning and Word Acquisition
Published on: July 13, 2019
17.0K
相关概念视频
Aneurysm II: Clinical Manifestations and Diagnostic Studies
10
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
10
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
